We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Common Cancer Gene Suppressed

By Biotechdaily staff writers
Posted on 23 May 2005
By studying laboratory mice with skin cancer, scientists have found a way to suppress a mutant gene called Ras, which is found in up to 30% of human tumors.

Ras is a cancer-causing gene, also known as an oncogene; normal copies of this gene are important in the cell-signaling process. More...
However, when mutated, Ras becomes an oncogene and can trigger the growth of tumors in the lung, colon, pancreas, as well as leukemia and thyroid cancer.

Efforts to inhibit activated Ras has had little success to date. However, researchers at the Huntsman Cancer Institute (Salt Lake City, UT, USA) reported that they have found an enzyme that, when inhibited, seems to reduce the incidence of Ras-induced tumors in mice. They published their findings in the May 9, 2005, online early edition of the Journal of the Proceedings of the [U.S.] National Academy of Sciences.

Matthew K. Topham, M.D., assistant professor of internal medicine at the University of Utah School of Medicine (Salt Lake City, UT, USA; www.utah.edu) and lead investigator on the study, explained that the researchers had initially been evaluating a group of enzymes that control the function of the Ras gene. These enzymes, called diacylglycerol kinases (DGKs), are implicated in tumor growth.

"When we began our investigation using a type of DGK, called DGK iota, we thought that its absence would cause more tumors to develop, as has happened with other DGKs we have tested. This time, though, when we tested mice with an activated Ras gene, but an absent DGK iota gene, the number of tumors was significantly reduced,” Dr. Topham remarked. "This result is interesting because it happened when the Ras gene was activated. The implication is that a drug therapy could be developed to reduce tumors caused by Ras without significant side effects.”

The investigators used mice that were bred to have a highly expressed mutant form of the Ras oncogene. Earlier studies showed that these mice were very prone to tumors. For the new study, the group of scientists removed the DGK iota gene in the mice and discovered they developed a small number of tumors, whereas mice with an intact DGK iota gene and an activated Ras gene showed considerably more tumor activity. Dr. Topham said his team will now more closely evaluate the process behind how DGK iota works to inhibit tumor formation.




Related Links:
Huntsman Cancer Institute

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
hCG Whole Blood Pregnancy Test
VEDALAB hCG-CHECK-1
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.